Thrombotic manifestations of antiphospholipid syndrome (APS) are well known, and various
non-stroke neuro-psychiatric manifestations (NPMs) have also been consistently described …

An increasing body of literature data suggests that inflammation, and in particular
neuroinflammation, is involved in the pathophysiology of particular forms of epilepsy and …

The place of non-criteria antiphospholipid antibodies (aPLs) in the diagnosis of
antiphospholipid syndrome (APS) is still debatable. The aim of this research was to evaluate …

Corticobasal syndrome (CBS) is a clinical entity, classified as an atypical Parkinsonism,
characterized by both motor and higher cortical dysfunctions. The clinical manifestation of …

Primary antiphospholipid syndrome (PAPS) and antiphospholipid syndrome associated to
lupus (SAPS) have several overlapping characteristics. As systemic manifestations are also …

Objectives Antiphospholipid syndrome (APS) is associated with neurological manifestations
and one of the novel autoantigens associated with this disease is Annexin A2 (ANXA2). In …

Objectives APS-associated heart valve disease (HVD) is well described. Nonetheless,
limited data exist on clinical parameters associated with the course of primary APS (pAPS) …

Antiphospholipid syndrome (APS) is a systemic autoimmune disorder mainly characterised
by increased risks of thrombosis and pregnancy morbidity and persistent positive test results …

Background: Antiphospholipid syndrome (APS) is an acquired autoimmune disorder defined
by the presence of both clinical (thromboembolic events or pregnancy morbidity) and …

Objective. The risk factors for incident seizures in systemic lupus erythematosus (SLE) were
prospectively determined in a cohort study. Methods. A total of 2203 patients with SLE …